LG Chem Acquires Worldwide Rights to First-in-Class p53 Y220C Cancer Drug FMC-220
核心洞察
LG Chem (搜索) has secured exclusive worldwide licensing rights to develop and commercialize FMC-220, a first-in-class covalent p53 Y220C activator, outside of Greater China through a partnership with Frontier Medicines (搜索).
FMC-220 targets the p53 Y220C mutation found in approximately 1-3% of cancers, particularly prevalent in solid tumors such as lung, breast, ovarian and colorectal cancers.
Preclinical data demonstrated that FMC-220 delivers unprecedented potency, selective engagement, and durable anti-tumor activity at low doses across a broad range of tumor models.
LG Chem (搜索) has acquired exclusive worldwide licensing rights to develop and commercialize FMC-220, a first-in-class covalent p53 Y220C activator, from US-based biotechnology company Frontier Medicines (搜索). The agreement grants LG Chem rights to the innovative cancer treatment outside of Greater China, while Frontier retains full ownership and control within Greater China.
Targeting the "Undruggable" p53 Protein
FMC-220 represents a breakthrough approach to targeting p53, a tumor suppressor protein that has long been considered "undruggable" due to its lack of binding pockets for small-molecule drugs. The drug specifically targets the p53 Y220C mutation, a common missense mutation found in approximately 1-3% of cancers, particularly prevalent in solid tumors such as lung, breast, ovarian and colorectal cancers.
"FMC‑220 is an innovative approach that targets genetic mutations with limited existing treatment options," said Son Jee-woong, president of LG Chem (搜索) Life Sciences. "We will work to validate its potential as a treatment option that could deliver benefits to patients."
Promising Preclinical Results
FMC-220 works by covalently binding the mutant cysteine residue introduced by the Y220C substitution in TP53 (搜索). Preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 demonstrated that FMC-220 delivers unprecedented potency, selective engagement, and durable anti-tumor activity at low doses across a broad range of tumor models, including those harboring co-mutations such as those in KRAS (搜索).
Clinical Development Plans
LG Chem (搜索) plans to begin Phase 1 clinical trials in both the US and Korea this year, initially focusing on ovarian cancer, where the p53 Y220C mutation is relatively more prevalent, before expanding into other solid tumors. The company will be responsible for regulatory filings, global clinical development and commercialization in the licensed territories.
Financial Terms and Partnership Structure
Under the licensing agreement, Frontier Medicines (搜索) will receive an upfront payment and is eligible to receive additional clinical, regulatory and commercial milestone payments, as well as mid-single-digit to double-digit royalties on net sales. The specific financial figures of the deal were not disclosed. Frontier retains an option for enhanced financial participation through partial funding of the confirmatory clinical trial.
"This partnership with LG Chem (搜索) marks an exciting and pivotal step for Frontier and for the FMC-220 program, underscoring the promise of our proprietary Frontier Platform to address historically challenging targets and deliver differentiated, covalent precision therapies," said Chris Varma, CEO of Frontier Medicines (搜索). "Through this collaboration with LG Chem, the FMC-220 program will continue to advance, progressing toward translating the encouraging preclinical data we have demonstrated to date for FMC-220 into meaningful impact for patients."